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Abstract 
Low-density lipoprotein receptor-related protein 1 (LRP1, also known as CD91), a multifunctional endocytic and cell 
signaling receptor, is widely expressed on the surface of multiple cell types such as hepatocytes, fibroblasts, neu-
rons, astrocytes, macrophages, smooth muscle cells, and malignant cells. Emerging in vitro and in vivo evidence 
demonstrates that LRP1 is critically involved in many processes that drive tumorigenesis and tumor progression. For 
example, LRP1 not only promotes tumor cell migration and invasion by regulating matrix metalloproteinase (MMP)-2 
and MMP-9 expression and functions but also inhibits cell apoptosis by regulating the insulin receptor, the serine/
threonine protein kinase signaling pathway, and the expression of Caspase-3. LRP1-mediated phosphorylation of the 
extracellular signal-regulated kinase pathway and c-jun N-terminal kinase are also involved in tumor cell proliferation 
and invasion. In addition, LRP1 has been shown to be down-regulated by microRNA-205 and methylation of LRP1 
CpG islands. Furthermore, a novel fusion gene, LRP1-SNRNP25, promotes osteosarcoma cell invasion and migration. 
Only by understanding the mechanisms of these effects can we develop novel diagnostic and therapeutic strategies 
for cancers mediated by LRP1.
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Background
Low-density lipoprotein receptor-related protein 1 
(LRP1, also known as CD91), a large endocytic recep-
tor initially described by Herz et al. [1] in 1988, belongs 
to the low-density lipoprotein receptor (LDLR) super-
family. LRP1 is the most multifunctional member of 
this superfamily [1, 2]. Many translational studies have 
shown that LRP1 is involved in two major physiological 
processes: endocytosis and regulation of signaling path-
ways [3–5]. LRP1 mediates the endocytosis of a diverse 
set of extracellular ligands that play important roles in 
tumor progression [6]. In addition, LRP1 can initiate and 
regulate diverse signaling pathways, including mitogen-
activated protein kinase (MAPK), insulin receptor (IR), 
serine/threonine protein kinase (AKT), extracellular 
signal-regulated kinase (ERK), and c-jun N-terminal 
kinase (JNK) pathways [7, 8]. Notably, these two physi-
ological processes play an important role in multiple bio-
logical activities, including regulation of cell growth and 
differentiation, modulation of cytoskeletal organization 
angiogenesis, cell migration, and regulation of protease 
degradation for tissue invasion. Hence, in this review, 
we focus on recent translational studies that describe 
the roles of LRP1 in cancer cell proliferation, apoptosis, 
migration, invasion, and angiogenesis.
From structure to function
The LDLR superfamily includes many members, such as 
LRP1, megalin (LRP2), LRP3, LRP4, LRP5, LRP6, very 
low-density lipoprotein receptor (VLDLR), and apolipo-
protein E (apoE) receptor type 2 (apoER2, also known as 
LRP8) [9]. These proteins share five structural domains: 
(1) ligand-binding type cysteine-rich repeats, (2) epi-
dermal growth factor (EGF) receptor-like cysteine-rich 
repeats, (3) YWTD domains, (4) a transmembrane 
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domain, and (5) a cytoplasmic tail that harbors up to 
three NPXY motifs (Fig. 1) [2]. LRP1 consists of a large 
extracellular ligand-binding subunit (515  kDa), trans-
membrane subunit, and short cytoplasmic tail (85 kDa) 
[10]. Structurally, LRP1 is made up of 31 class A 
cysteine-rich repeats and an extracellular domain com-
prised of 4 ligand-binding clusters (I–IV), which have 
2, 8, 10, and 11 complement-type repeats, respectively 
(Fig.  1) [11]. Domains II and IV mediate the binding 
of LRP1 to more than 40 ligands, including apolipo-
protein, proteinases, proteinase-inhibitor complexes, 
bacterial toxins, viruses, the blood coagulation factor 
VIII, and various extracellular matrix proteins such as 
matrix metalloproteinases (MMPs) and urokinase-type 
plasminogen activator (uPA) [2, 12]. In contrast to 
LDLR, VLDLR, LRP2, and apoER2, the cytoplasmic 
tail of LRP1 contains 1 YXXL motif and 2 NPXY motifs 
(Fig.  1). The NPXY motifs function as the endocytosis 
signal for the LDLR family, and the YXXL motif serves 
as the dominant signal for rapid endocytosis of LRP1 
[13, 14]. Therefore, the primary function of LRP1 is to 
bind ligands via the extracellular ligand-binding domain 
and promote their internalization via its cytoplasmic 
tail. Furthermore, LRP1 delivers bound ligands to the 
endosomal/lysosomal compartment for release and then 
returns to the cell membrane for reuse [15]. In addi-
tion to the endocytosis of multiple ligands, more recent 
studies have reported that LRP1 interacts and activates 
a diverse set of signaling proteins. Recently, Mantuano 
et al. [5] reported that some proteins can bind to LRP1 
and activate LRP1-dependent signaling molecules such 
as ERK1/2. Within this context, proteins such as tissue-
type plasminogen activator (tPA), apoE, and activated 
α2-macroglobulin (α2M) function as ligands of LRP1 [5]. 
In addition, substantial evidence indicates that LRP1 
can activate various signaling pathways in response to 
particular ligands that bind to its extracellular domain 
by other mechanisms. For example, LRP1 binds to the 
platelet-derived growth factor (PDGF) receptor and 
forms a receptor-ligand complex that then activates 
the MAPK signaling pathway by driving endocytosis 
of the complex [4]. LRP1 has also been shown to acti-
vate signaling pathways by changing the levels of related 
receptors such as the uPA receptor (uPAR) [16]. Impor-
tantly, deregulation of the above signaling pathways 
has been implicated in tumor cell invasion and prolif-
eration [4, 17]. Therefore, it is likely that, in addition to 
clearing the extracellular environment, LRP1-mediated 
endocytosis of ligands contributes to the delivery of 
cancer-promoting signals in cells. Consequently, LRP1 
is suggested to be involved in two major cell processes: 
endocytosis and modulation of signaling pathways, 
which play diverse biological roles in cancer cells. Taken 
together, the unique structure of LRP1 contributes to its 
multi-functionality.
Association between LRP1 and cancer 
susceptibility
The relationship between LRP1 and a variety of can-
cers has been reported. For example, Benes et  al. [18] 
observed polymorphic alleles of C766T in exon 3 of 
LRP1 gene and a marked increase in the frequency of the 
LRP1 T allele in patients with breast cancer compared 
with control populations (0.21 versus 0.15, P = 0.01963), 
suggesting that the T allele of C766T in the LRP1 gene 
may increase the risk of breast cancer. In addition, LRP1 
gene amplification has been found in astrocytoma, with 
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Fig. 1 Structures of low-density lipoprotein receptor-related protein 
1 (LRP1) and very low-density lipoprotein receptor (VLDLR). This 
Figure is modified from Figure 1 of a review written by Herz et al. [2]. 
The large extracellular ligand-binding subunit of LRP1 consists of 4 
different ligand-binging clusters that contain 2, 8, 10, and 11 cysteine-
rich ligand-binding repeats, respectively (red dots). Each cluster 
contains 1–4 epidermal growth factor (EGF) precursor homology 
domains, which include 2 cysteine-rich EGF repeats (blue circles) and 
6 YWTD domains (blue lines). The cytoplasmic tail of LRP1 contains 2 
NPXY motifs (marked with an asterisk). In addition, the cytoplasmic tail 
of LRP1 has 1 YXXL motif. Compared with LRP1, VLDLR is smaller. In 
addition, the O-linked sugar domain of VLDLR is enriched with serine 
and threonine residues (blue hexagon). Moreover, the cytoplasmic 
tail of VLDLR contains only 1 NPXY motif. Thus, the structure of LRP1 
determines the endocytosis of ligands
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68  % of high-grade astrocytomas (grade IV) exhibit-
ing high expression of LRP1, compared with the lack of 
LRP1 expression observed in 91  % of normal brain tis-
sues [19]. Moreover, compared with low-grade astro-
cytoma, malignant glioma has been characterized with 
significantly higher levels of LRP1 mRNA and protein 
[20]. In addition, increasing levels of LRP1 expression is 
commonly observed in the majority of endometrial car-
cinomas, suggesting that LRP1 is involved in the forma-
tion of endometrial carcinoma [21]. Tumorigenesis is a 
multistep process that involves cancer cell proliferation, 
angiogenesis, invasion, and migration [22]. Therefore, 
it is likely that LRP1 is involved in modulating some of 
these processes.
The role of LRP1 in regulating cancer cell invasion 
and migration
LRP1‑mediated regulation of MMP expression promotes 
cancer cell migration and invasion
It is well known that MMPs, especially MMP-2 and 
MMP-9, are significantly involved in the invasion and 
metastasis of several types of human tumors [23, 24]. 
Recently, Song et  al. [25] reported that LRP1 regulates 
the expression of MMP-2 and MMP-9, thereby promot-
ing the migration and invasion of U87 human glioblas-
toma cells. In their study, knockdown of LRP1 using 
LRP1 small interfering RNA in the human glioblastoma 
cell line U87 led to a decrease in cell migration and inva-
sion, which suggests that the expression level of LRP1 
is associated with migration and invasion capabilities 
of these cancer cells. Using LRP1-deficient and LRP1-
overexpressing mouse embryonic fibroblasts cells, Song 
et  al. [25] confirmed that LRP1-regulated MMP-2 and 
MMP-9 expression was involved in cell migration and 
invasion. In addition, they found that the level of phos-
phorylated ERK was decreased in LRP1-silenced cells, 
whereas other signaling pathways remained unchanged, 
suggesting that LRP1 regulates the expression of MMP-2 
and MMP-9 via an ERK-dependent signaling pathway 
(Fig. 2) [25–27].
Other mechanisms have also been shown to contrib-
ute to LRP1-mediated MMP-dependent cancer cell 
invasion and migration. One study showed that the 
binding of the serine protease inhibitor protease nexin-1 
(PN-1) to LRP1 stimulates MMP-9 expression, thereby 
promoting metastasis of breast cancer [28]. Similarly, 
α2M was shown to activate proMMP-2 via binding to 
LRP1 and promote the migration of human Müller glial 
cells [29]. However, α2M can also inhibit cell invasion 
through the clearance of pepsin from the extracellular 
environment [30, 31]. Thus, the role and mechanism 
of α2M in cell invasion and migration requires further 
investigation.
LRP1‑dependent activation of ERK and inhibition of JNK 
promote cancer cell invasion
Another mechanism by which LRP1 promotes can-
cer cell invasion is via activation of ERK and inhibition 
of JNK signaling pathways, which are two major MAPK 
pathways (Fig.  2). One study found that the level of 
phosphorylated ERK-1/2 was selectively decreased in 
LRP1-silenced cancer cells, whereas the level of phospho-
rylated JNK-1/2/3 was increased in cells, suggesting that 
LRP1 may serve as an intracellular signaling regulator 
by regulating the ERK and JNK signaling pathways [17]. 
Furthermore, these results are consistent with those of 
previous studies performed in fibroblasts, Schwann cells, 
and other non-tumor cells [32, 33]. In addition, the ERK 
signaling pathway has been shown to be activated during 
tumor cell invasion, and the invasion of JNK-overexpress-
ing tumor cells is reduced, suggesting that ERK activation 
and JNK inhibition are required to promote tumor cell 
invasion [17]. Notably, the initial activation of the MAPK 
pathway is driven by the binding of LRP1 to PDGFR-bet 
in endosomes (Fig. 2) [4]. Future studies will be required 
to investigate the location of MAPK binding to LRP1.
Role of the eHsp90‑LRP1 signaling complex in tumor cell 
invasion and migration
Gopal et  al. [20] identified a novel extracellular heat 
shock protein 90 (eHsp90) that can bind to LRP1 and 
form an eHsp90-LRP1 signaling complex in glioblastoma 
multiforme (GBM) (Fig.  2). The eHsp90-LRP1 complex 
was shown to regulate activation of the receptor tyrosine 
kinase EphA2, which is frequently overexpressed in most 
GBMs and stimulates GBM cell motility and invasion fol-
lowing activation by AKT-dependent phosphorylation at 
S897 (p-EphA2S897) (Fig.  2). In addition, positive feed-
back signaling from eHsp90 further activates AKT and 
promotes recruitment of LRP1 to EphA2 (Fig. 2), thereby 
strengthening this signaling pathway and highlighting a 
novel mechanism of LRP1-mediated regulation of tumor 
cell migration and invasion. In addition, the aforemen-
tioned mechanism is augmented during cellular hypoxia, 
which subsequently enhances the eHsp90-LRP1 signaling 
axis due to increased expression of LRP1 and eHsp90 [20, 
34]. Collectively, these studies provide novel insight into 
how eHsp90-LRP1 promotes tumor cell migration and 
invasion and may lead to new therapeutic approaches to 
suppress the aggressiveness of GBM.
Controversial data concerning the role of LRP1 in cancer 
cell invasion and migration
An increasing number of studies have confirmed that 
LRP1 promotes cancer cell invasion and migration. How-
ever, some investigations suggest that low expression 
of LRP1 can also promote tumor cell progression. uPA 
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has been shown to be involved in tumor progression in 
a variety of cancers [35]. In human thyroid cancer cells, 
inhibiting LRP1 expression or increasing the level of uPA 
has been shown to enhance tumor cell invasion, specifi-
cally driving metastasis from lymph nodes and the lung 
[36]. Thus, low expression of LRP1 on the cell surface 
couples to increased expression and bioactivity of uPA 
and promotes tumor cell invasion [36]. Similarly, in fibro-
blasts, it has been reported that LRP1 inhibits cell migra-
tion by decreasing the cell surface abundance of uPA 
[16]. The mechanism of this function involves uPA bind-
ing to uPAR and activating plasminogen, which initiates 
a hydrolysis cascade of related proteins that drives deg-
radation of the extracellular matrix. These processes 
facilitate tumor cell invasion through cell boundaries and 
hence, play a critical role in the migration of tumor and 
non-tumor cells [16]. Furthermore, a recent study has 
demonstrated that high expression of LRP1 is associated 
with a low metastatic potential of hepatocellular car-
cinoma (HCC) [37]. In addition, this study showed that 
inhibition of LRP1 increased the expression and bioactiv-
ity of MMP-9 in HCC cells. These results suggest a nega-
tive association between LRP1 and MMP-9 expression in 




























Fig. 2 Low-density LRP1-mediated cell signaling pathways. LRP1 regulates several signaling pathways in a phosphorylation-dependent manner. 
These pathways are involved in several processes of tumorigenesis and progression. Binding of LRP1 to platelet-derived growth factor (PDGF) recep-
tor activates the mitogen-activated protein kinase (MAPK) signaling pathway, which subsequently activates the extracellular signal-regulated kinase 
(ERK) pathway and inhibits c-jun N-terminal kinase (JNK), resulting in cancer cell invasion and proliferation. In addition, ERK increases the transcrip-
tional levels of matrix metalloproteinase (MMP)-2 and MMP-9, which drive cancer cell invasion. LRP1 activates the serine/threonine protein kinase 
(AKT) signaling pathway and insulin receptor (IR), which inhibits cancer cell apoptosis. LRP1 binds to the novel extracellular heat shock protein 90 
(eHsp90) and forms an eHsp90-LRP1 signaling complex, which stimulates glioblastoma multiforme cell motility and invasion via AKT-dependent 
phosphorylation at S897 (p-EphA2S897). The eHsp90 signaling regulates AKT activation and facilitates recruitment of LRP1 to the receptor tyrosine 
kinase EphA2
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in U87 human glioblastoma cells [25]. Similar examples 
have also been found in other types of cancers, such as 
human endometrial carcinoma [38], breast and pros-
tate cancers [39], lung cancer [40], and Wilm’s tumors 
[41]. Therefore, these data suggest that LRP1 may have 
a dual role in cancer cell invasion and migration, which 
potentially depends on the different cell type and specific 
extracellular microenvironment.
The role of LRP1 in regulating cancer cell apoptosis 
and proliferation
Mounting evidence suggests that LRP1 plays an impor-
tant role in cell proliferation and apoptosis. Fuentealba 
et  al. [8] found that knockdown of LRP1 by short hair-
pin RNA in neurons significantly decreased the levels 
of Caspase-3 activation, AKT phosphorylation, IR sign-
aling, and apoptosis. Caspase-3 is a key enzyme in cell 
apoptosis, suggesting that LRP1 may also inhibit cancer 
cell apoptosis by regulating the activation of Caspase-3. 
Moreover, the important role of LRP1 in activating the 
AKT and IR signaling pathways has been confirmed in 
the forebrain of LRP1-ablated mice, which were char-
acterized with decreased cell apoptosis, suggesting 
that LRP1 inhibits apoptosis by activating the IR and 
AKT signaling pathways (Fig.  2) [8]. Subsequent stud-
ies have revealed the mechanism by which LRP1 acti-
vates the AKT signaling pathway and that α2M can bind 
to LRP1 and activate AKT in Schwann cells [32]. How-
ever, the specific LRP1-mediated mechanism of activa-
tion remains unclear. In addition, one study reported that 
LRP1 is involved in PDGF-mediated activation of ERK 
phosphorylation, which can increase smooth muscle cell 
and fibroblast proliferation [4]. Thus, LRP1 can regulate 
cell apoptosis, proliferation, invasion, and migration.
Unique role of monocyte‑ 
and macrophage‑associated LRP1 in tumorigenesis 
and tumor progression
Monocytes and macrophages promote cell invasion, 
metastasis, and angiogenesis in multiple cancers [42, 
43]. In the initial step of tumor formation, macrophages 
create an inflammatory environment that promotes the 
growth of tumor cells. These growth-promoting effects 
on tumors are caused by the expression of multiple fac-
tors such as tumor necrosis factor-α and interleukin-6 
[44, 45]. Moreover, macrophages produce EGF, which 
activates migration of tumor cells [46]. In addition, mac-
rophages have been implicated in tumor angiogenesis. 
Accumulating studies reported that LRP1 in monocytes 
and macrophages plays a critical role in cancer progres-
sion by acting as a regulator of inflammation [45]. Staudt 
et  al. [47] implanted PanO2 pancreatic carcinoma cells 
into mice that harbored LRP1-deficient myeloid cells 
and found that monocytes were strongly recruited to 
carcinoma cells. In addition, LRP1-deficient, bone mar-
row-derived macrophages expressed high levels of mac-
rophage inflammatory protein-1α/CCL3 [47]. These 
findings suggest a negative association between LRP1 
expression and the recruitment of monocytes and mac-
rophages. Moreover, tumor-associated, LRP1-deficient 
macrophages were characterized by the release of vas-
cular endothelial growth factor (VEGF) into the tumor 
microenvironment [47]. The level of VEGF is closely 
associated with microvessel density and the malignant 
degree of tumors and is increasing in tumor tissues 
compared with non-tumor tissues [47], suggesting that 
VEGF may promote tumorigenesis by regulating LRP1 to 
enhance angiogenesis. Together, the roles of monocyte- 
and macrophage-associated LRP1 in the initiation and 
progression of tumor suggest that targeted regulation of 
the inflammatory environment may prevent the occur-
rence of tumors.
The multiple roles of LRP1 CpG island methylation
Accumulating evidence suggests that DNA methylation 
of CpG islands plays a critical role in the initiation and 
progression of multiple cancer types [48, 49]. The pro-
moter region of LRP1 is enriched with CpG islands that 
govern sensitivity of the LRP1 gene to DNA methylation. 
Moreover, all constructs containing CpG sequences can 
increase transcriptional activity. Sonoda et al. [50] stud-
ied the methylation status of LRP1 CpG islands in esoph-
ageal squamous cell carcinomas (ESCCs) and found that, 
when CpG was methylated completely, the transcrip-
tional activity completely disappeared and the expression 
of LRP1 was silenced. Moreover, the methylation of LRP1 
CpG islands was frequently observed in ESCC cells com-
pared with control cells. Furthermore, when the expres-
sion of LRP1 was recovered, the growth of these ESCC 
cells was inhibited [50]. These data suggest that LRP1 
CpG island methylation may be involved in tumor pro-
gression by controlling the expression of LRP1. In addi-
tion, methylation of LRP1 CpG islands may represent a 
novel diagnostic marker for ESCC and other cancers.
microRNA‑205 (miR‑205) and LRP1
MicroRNAs are small noncoding RNAs that play a criti-
cal role in regulating post-transcriptional gene expres-
sion in various human cancers and are involved in 
driving tumorigenesis via regulation of metastasis, inva-
sion, cell proliferation, and apoptosis [51]. Song et al. [52] 
examined U87 glioblastoma and SK-LU-1 lung adeno-
carcinoma cells, which express high levels of LRP1, and 
found that LRP1 expression and cell migration were 
both suppressed in cells transfected with miR-205. They 
also demonstrated that miR-205 suppressed LRP1 gene 
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expression via inhibition of translation. Moreover, endo-
cytosis of α2M, a ligand of LRP1, was significantly sup-
pressed in these cells [52]. Together, these data suggest 
that miR-205 down-regulates LRP1 expression and its 
endocytic function and leads to suppressed tumor cell 
migration and invasion [52]. Song et al. [52] also revealed 
the mechanism by which miR-205 causes LRP1 gene 
silencing. miR-205 binds to its complementary sequences 
in the 3′ untranslated regions of LRP1, which plays a role 
in regulating LRP1 expression. Consistent with this find-
ing, Kajihara et  al. [53] recently reported that miR-205 
down-regulated LRP1 expression and suppressed ERK 
phosphorylation, thereby inhibiting cell proliferation in 
dermatofibrosarcoma protuberans. Consequently, these 
results highlight a potential tumor suppressive function 
of miR-205 via regulating the expression of LRP1.
Novel LRP1‑SNRNP25 fusion gene in osteosarcoma
Recently, a novel fusion gene, LRP1-SNRNP25, was iden-
tified in human osteosarcoma by transcriptome sequenc-
ing, reverse transcription-polymerase chain reaction, and 
Sanger sequencing [54]. LRP1 and SNRNP25 are located 
on 12q and 16p, respectively. Sanger sequencing revealed 
that LRP1-SNRNP25 is formed by linking exon 8 of LRP1 
to exon 2 of SNRNP25. Fluorescence in  situ hybridiza-
tion not only confirmed that the fusion gene was resulted 
from interchromosomal rearrangement but also identi-
fied the amplification of the LRP1-SNRNP25 fusion gene. 
In addition, transfection of LRP1-SNRNP25 into SAOS-2 
human osteosarcoma cells showed that the expression of 
LRP1-SNRNP25 promotes SAOS-2 cell migration and 
invasion [54, 55]. Importantly, this novel finding may lead 
to a new therapeutic approach for osteosarcoma.
Conclusions
The ability of LRP1 to promote endocytosis and deliver 
cell signaling suggests that LRP1 may play multiple roles 
in tumorigenesis and tumor progression. In addition, 
LRP1 has dual effects on tumor cell invasion and migra-
tion, reinforcing that the tumor cell-specific activity of 
LRP1 must be studied in the future. Moreover, LRP1 can 
be regulated via methylation of LRP1 CpG islands as well 
as miR-205, which further complicates the role of LRP1 in 
cancer cells. LRP1 also serves as a regulator of monocytes 
and macrophages. Recently, the roles of the immune sys-
tem in the initiation and progression of multiple cancers 
have received increasing attention. Thus, there are multi-
ple opportunities to develop new LRP1-related diagnostic 
and therapeutic approaches for many types of cancers.
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